INTRODUCTION {#sec1-1}
============

Juvenile myasthenia gravis (JMG) is a rare autoimmune disorder resulting in muscle weakness. It is an antibody-mediated disease affecting the postsynaptic neuromuscular junction, resulting in the blockade of synaptic transmission. Immune-mediated injury results in a myriad of clinical manifestations that can include ocular, bulbar, and generalized muscle weakness. Of all patients with myasthenia gravis (MG), 10 to 20% are infants and children who can present with congenital, transient neonatal, or most commonly JMG. Most large series describing the anesthetic management of MG are on adult patients.\[[@CIT1]\] Although the adult and juvenile forms of MG share a similar pathophysiology and clinical presentation, the epidemiology, prognosis, and some aspects of treatment are different for JMG.\[[@CIT2]\] Apart from an older series,\[[@CIT3]\] most reports on the current anesthetic management in children are case reports.\[[@CIT4]\] We present a case series of the perioperative management of patients with JMG undergoing transsternal thymectomy.

METHODS {#sec1-2}
=======

Medical records of patients undergoing transsternal thymectomy for management of JMG at our institution between 2000 and 2009 were reviewed retrospectively. Patients without MG undergoing thymectomy for other indications were not included. This study was approved by the hospital's Committee for Clinical Investigation and consent requirement was waived. Interest was only in the perioperative course, not in the long-term medical outcome of the surgery. Information obtained included patient demographics (age, weight, gender, symptoms, antibody status, and previous medical management), anesthetic management aspects (use of induction and maintenance agents, muscle relaxants, opioids and anticholinesterases, epidural analgesia), and perioperative course (extubation success, postoperative analgesia, postoperative plasmapheresis, intensive care unit duration, and overall length of hospital stay).

RESULTS {#sec1-3}
=======

A total of 13 patients were identified, ranging from 6 to 22 years (mean, 13.2 years) in age and from 21 to 79 kg (mean, 50.3 kg) in weight. Patient demographics, clinical symptoms, and preoperative medical management are summarized in detail in [Table 1](#T0001){ref-type="table"}. JMG was diagnosed 3 months to 6 years before surgery. Ocular symptoms were the most common presentation. Because generalized muscle weakness was uncommon, only a few patients had perioperative pulmonary function tests performed. All patients had undergone multiple treatment modalities and presented for surgery because of inadequate symptom control with medical treatment. Twelve patients were antibody-positive. One patient (patient 5) had JMG and a thymoma. One patient (patient 12) developed MG symptoms after a previous thymectomy for thymoma and underwent repeat sternotomy for resection of residual thymic tissue. Patients were continued on their routine schedule of pyridostigmine until the morning of surgery. Patients on long-term steroids as part of their MG management received supplemental steroids perioperatively to account for potential adrenal suppression. Ten patients underwent preoperative plasmapheresis as part of the preoperative regimen to optimize their status.

###### 

Patient characteristics

  Patient   Age (years)   Weight (kg)   Gender   Duration of symptoms   Symptoms o/b/g   Antibodies   Medical management                                       Preoperative plasmapheresis
  --------- ------------- ------------- -------- ---------------------- ---------------- ------------ -------------------------------------------------------- -----------------------------
  1         10            40            F        6 months               o/g              Positive     Pyridostigmine(180mg tid, 60mg tid), Steroid, IVIg       Yes
  2         8             32            F        6 years                o                Positive     Steroid only                                             No
  3         15            63            F        3 months               b/g              Positive     Pyridostigmine (90mg every 4 h), IVIg                    Yes
  4         18            75            F        3 months               o/b/g            Positive     Pyridostigmine (60mg three times daily)                  Yes
  5         15            68            M        5 months               o/b/g            Positive     Pyridostigmine (60mg every 6 h)                          Yes
  6         16            52            F        1 year                 o/b/g            Positive     Pyridostigmine (30mg every 6 h), IVIg                    No
  7         17            79            F        4 months               o/b/g            Positive     Pyridostigmine (45mg every 6 h)                          Yes
  8         18            59            F        1 year                 o/b/g            Positive     Pyridostigmine (60mg every 6 h)                          Yes
  9         9             43            M        6 months               o/b/g            Positive     Pyridostigmine (60mg every 4 h), Steroid, IVIg,          Yes
  10        6             21            M        2 years                o/g              Negative     Pyridostigmine (15mg every 12 h/30mg every 12 h), IVIg   No
  11        12            43            F        5 months               o/b/g            Positive     Pyridostigmine (60mg every 6 h)                          Yes
  12        6             26            M        1 month                o/g              Positive     Pyridostigmine (40mg every 4 h), IVIg                    Yes
  13        22            53            F        12 months              o/b              Positive     Pyridostigmine (60mg every 6 h)                          Yes

Gender: f = Female, m = Male. Symptoms: o = Ocular, b = Bulbar, g = Generalized weakness, IVIg = Intravenous immunoglobulin

[Table 2](#T0002){ref-type="table"} lists the anesthetic and postoperative details. Anesthesia was conducted at the discretion of the attending anesthesiologist. Standard ASA monitoring was used in all patients and eleven patients had invasive arterial blood pressure monitoring. Five children underwent inhalation induction and the remaining eight patients had an intravenous induction. None of the patients received muscle relaxants for intubation or during surgery. Before intubation, 4% topical lidocaine was applied to the vocal cords and trachea in most patients. A remifentanil infusion was started before intubation in eleven patients, one of whom developed self-limited bradycardia during intubation. All patients were offered epidural analgesia. Nine patients consented and underwent successful epidural catheter placement. This was done either awake-sedated prior to or asleep after induction of anesthesia, depending on the patient's age and ability to cooperate with the epidural catheter placement. Anesthesia was maintained with low-dose inhalation agent and remifentanil or other IV opioids. If an epidural catheter had been placed, it was used as part of the anesthetic. Pyridostigmine was given to six patients intraoperatively. Blood loss was minimal and no patient required a blood transfusion. Upon completion of surgery, patients were awakened and breathing efforts and muscle strength were assessed clinically by tidal volume, strength of cough, hand grip, and head lift. Patients with preoperative generalized muscle weakness reported decreased strength in the immediate postoperative period and clinically demonstrated muscle weakness. Twelve patients were extubated in the operating room. One teenager (patient 3) indicated that upon awakening, she felt uncomfortable breathing without support; she was extubated 9 hours later in the intensive care unit (ICU). All patients were electively admitted to the ICU after surgery. One patient (patient 12) with severe preoperative weakness required postoperative bi-level positive airway pressure (BIPAP) support. Initial postoperative pain control was achieved with epidural analgesia in seven patients, and two patients had combined epidural local anesthetic and intravenous morphine patient-controlled analgesia (PCA). In four patients, postoperative pain control was achieved with intravenous opioid PCA only.

###### 

Intra and postoperative course summary

  Patient   Preop sedation        Induction                                        Muscle relaxant   Maintenance                                         Remifentanil mcg/kg/min   Opioid intraop       Epidural level   AChEl intraop                      Ex-tubation    Postop analgesia               Epi-dural days   Postop plasmapheresis   ICU days   Hospital day
  --------- --------------------- ------------------------------------------------ ----------------- --------------------------------------------------- ------------------------- -------------------- ---------------- ---------------------------------- -------------- ------------------------------ ---------------- ----------------------- ---------- --------------
  1         None                  8% Sevoflurane                                   No                0.4-0.8% Isoflurane 70% nitrous                     0.5                       None                 T5/6             Neostigmine 2img                   OR             Epidural (BUP/HM)              2                Yes                     2          5
  2         None                  8% Sevoflurane Propofol 6omg                     No                0.8-1.2% Isoflurane                                 0.4                       Morphine             none             No                                 OR             Morphine PCA                   \-               No                      2          3
  3         Midazolam lmg (IV)    Propofol 200mg Fentanyl 250mcg                   No                0.4-1% Isoflurane 70% nitrous                       0.25                      Fentanyl, morphine   none             Pyridostigmine 3mg                 9 hrs postop   Morphine PCA                   \-               Yes                     1          4
  4         Midazolam 2mg (IV)    Thiopental 125mg Propofol isomg                  No                0.4-0.6% Isoflurane 70% nitrous                     0.1-0.3                   Fentanyl, morphine   none             Neostigmine 3-5mg                  OR             Morphine PCA                   \-               No                      1          4
  5         Midazolam 4mg (IV)    Thiopental 125img Fentanyl l00mcg                No                1-1.5% Isoflurane                                   None                      Fentanyl             T4/5             Pyridostigmine 2mg                 OR             Epidural (BUP) Morphine PCA    5                Yes                     1          8
  6         None                  8% Sevoflurane Thiopental 125mg Propofol 200mg   No                1.9-2.2% Sevoflurane propofol (150-200mcg/kg/min)   0.1-0.3                   None                 T5/6             Neostigmine 0.25mg (given twice)   OR             Epidural (BUP/HM)              3                No                      1          4
  7         Midazolam 4mg (IV)    Propofol 250mg Fentanyl l00mcg                   No                \<0.7% Sevoflurane 50% nitrous                      0.1-0.2                   Fentanyl, morphine   T6/7             No                                 OR             Epidural (BUP/ HM/C)           2                Yes                     1          4
  8         Midazolam 2mg (IV)    Propofol 150mg Fentanyl 25mcg                    No                \<1% Sevoflurane 50% nitrous                        0.2                       Fentanyl             T 9/10           No                                 OR             Epidural (BUP/HM)              3                Yes                     2          6
  9         Midazolam 2omg (po)   8% Sevoflurane                                   No                1-1.8% Sevoflurane 70% nitrous                      0.15                      None                 T7/8             No                                 OR             Epidural (BF) Morphine PCA     2                Yes                     1          7
  10        None                  8% Sevoflurane                                   No                \<1.5% Isoflurane 50% nitrous                       0.2                       None                 T8/9             Pyridostigmine lmg                 OR             Epidural (BUP/HM)              3                No                      1          4
  11        None                  Thiopental 50mg Propofol 200mg Fentanyl l00mcg   No                0.8% Isoflurane propofol (l00mcg/ kg/min)           0.2                       Fentanyl             T5/6             No                                 OR             Epidural (BF changed to BFC)   3                Yes                     1          5
  12        Midazolam 2mg (IV)    Propofol l00mg                                   No                1.2% Isoflurane 50% nitrous                         None                      Fentanyl, morphine   T7/8             No                                 OR             Epidural (BFC)                 5                Yes                     4          9
  13        Midazolam 6mg (IV)    Propofol 200mg Fentanyl l00mcg                   No                \<2% Sevoflurane                                    0.2                       Fentanyl, morphine   None             No                                 OR             Morphine PCA                   \-               Yes                     3          5

AChEI=acetylcholinesterase inhibitor. PCA=patient controlled opioid analgesia. BUP=bupivacaine 0.1%, HM=hydromorphone 10mcg/ml, C=clonidine 0.4mcg/ml, F=fentanyl 2mcg/ml

DISCUSSION {#sec1-4}
==========

JMG can affect children as young as 1 year of age.\[[@CIT2]\] There is a female predominance in patients of 10 years and older, which is similar to the adult form, but gender discrepancy does not exist for the younger children with JMG.\[[@CIT2]\] Fluctuating motor weakness is the hallmark of the disease. Prepubertal JMG is more likely to have isolated ocular symptoms such as ptosis and diplopia, whereas generalized muscle weakness and fatigability is more common in the postpubertal presentation. However, children with JMG tend to have fewer generalized symptoms compared with adults.\[[@CIT2]\] Patients may also have proximal limb weakness or bulbar symptoms, which affects their ability to chew, swallow, and articulate. More serious symptoms involve weakness of the diaphragm, which may result in respiratory distress.

Although JMG is typically a clinical diagnosis, antibody studies can help confirm the diagnosis. 80% of adult patients will test positive for acetylcholine receptor antibodies as opposed to 50% of prepubertal cases of JMG.\[[@CIT2]\] Seronegative patients may test positive to autoantibodies targeting muscle-specific kinase. These patients also have disruption at the postsynaptic neuromuscular junction, but it is caused by a different antigen. Further testing includes the edrophonium test, repetitive nerve stimulation, and single fiber electromyography. Chest radiograph and computed tomography are performed to investigate for the presence of a thymoma which occurs less commonly in JMG than in adult MG. Cooperative patients with generalized weakness should undergo pulmonary function testing preoperatively and postoperatively.

Medical management depends on the severity of JMG and the response to treatment. The clinical course of JMG can be fluctuating with intermittent remissions and exacerbations. Children tend to have higher rates of spontaneous remission than adults.\[[@CIT2]\] Pyridostigmine, a long-acting acetylcholine esterase inhibitor (AChEI), is the first-line therapy. It prevents acetylcholine breakdown, and subsequently increases the synaptic acetylcholine concentration which improves neuronal transmission. Patients with progressive symptoms are treated with high-dose steroids and other immunosuppressant drugs such as cyclosporine and azathioprine.\[[@CIT5]\] Steroids are often used cautiously in children because of the long-term side effects. Intravenous immunoglobulin (IVIg) and plasmapheresis frequently provide symptomatic improvement which is utilized perioperatively and during exacerbations and myasthenic crisis. Laboratory perturbations seen with plasmapheresis that may affect the perioperative course include coagulopathies, anemia, hypoalbuminemia, and hypocalcemia. Unfortunately, IVIg and plasmapheresis seem to have poor long-term benefits for most patients.\[[@CIT5]\]

Patients resistant to medical treatment can be offered thymectomy, which may decrease morbidity from JMG.\[[@CIT6]\] Hyperplastic thymus, not thymoma, is the most common abnormality found in children with JMG who have undergone thymectomy. Unlike adults, thymectomy within 2 years of presentation may result in a higher rate of remission in Caucasian children.\[[@CIT2]\] Thymectomy can be performed through a transcervical, thoracoscopic, or transsternal approach. Complete resection of the thymus is best achieved through transsternal thymectomy, as thymic tissue may be widely distributed in the pretracheal and anterior mediastinal fat.\[[@CIT7]\]

Based on the literature, no particular anesthetic technique has proven superior for thymectomy in JMG. A variety of inhalational and intravenous techniques have been used successfully. Total intravenous anesthesia avoids the muscle relaxing effect of inhalational agents\[[@CIT8]\] and may facilitate early extubation,\[[@CIT9]\] but does not have clinical advantages.\[[@CIT10][@CIT11]\] Muscle relaxants are not generally contraindicated but should be used with caution. Due to the decreased receptor density, patients with JMG are resistant to succinylcholine. Although an increased succinylcholine dose may be required, its duration of action may be prolonged in the presence of AChEIs. Patients with JMG are sensitive to nondepolarizing muscle relaxants, which must be administered in reduced doses and titrated carefully. We prefer to avoid the use of muscle relaxants. Remifentanil is a useful adjunct to help achieve an adequate anesthetic depth for tracheal intubation and to prevent intraoperative patient movement, while facilitating the rapid return of adequate respiratory function for emergence.\[[@CIT4][@CIT12]\] We did not notice a prolonged duration of action for remifentanil, which is a concern in patients with JMG taking AChEIs or with decreased levels of plasma esterases from preoperative plasmapheresis.\[[@CIT13]\]

Successful use of regional anesthesia has been reported for patients with MG. Epidural analgesia has been used for transsternal thymectomy both with\[[@CIT4][@CIT12]\] and without\[[@CIT14]\] general anesthesia. It reduces the need for intraoperative and postoperative systemic opioids and may promote early extubation.\[[@CIT15]\] We did not see a detrimental effect of epidural local anesthetic use on respiratory muscle strength. Ester local anesthetics should be avoided in patients taking AChEIs.

There are no clear guidelines regarding perioperative administration of AChEIs. Older reports indicated increased postoperative complications with perioperative AChEI administration and recommended avoiding them preoperatively.\[[@CIT3]\] However, advising patients to withhold their preoperative dose may result in increased muscle weakness. In contrast, patients who continue to take their pyridostigmine may have increased secretions or develop a cholinergic crisis with muscarinic symptoms (nausea, sweating, miosis, and bradycardia). Severe bradycardia is a concern in patients on AChEIs, with anesthetic techniques utilizing remifentanil,\[[@CIT16]\] high thoracic epidural local anesthetics,\[[@CIT17]\] or spinal anesthesia,\[[@CIT18]\] particularly with vagal stimulation occurring during intubation. As reported by others,\[[@CIT3]\] one of our patients developed severe but self-limited sinus bradycardia during intubation. For subsequent cases, we administered an anticholinergic agent preemptively. We give the patient's routine AChEI dose up to the time of surgery. We no longer administer an intravenous AChEI dose during surgery, but wait until a postoperative clinical evaluation is possible and the patient can resume oral medication.

The need for high preoperative doses of pyridostigmine and reduced preoperative pulmonary function was associated with postoperative respiratory complications in patients with MG.\[[@CIT19]--[@CIT21]\] Similarly, all of our patients with no or only mild systemic weakness were extubated successfully in the operating room and had no perioperative problems related to their disease or the anesthetic. Patients with more severe systemic weakness reported increased weakness with emergence, despite the avoidance of muscle relaxants. Only one patient required brief postoperative ventilation. All of our patients were taken to the ICU for postoperative monitoring, pain control, plasmapheresis, and respiratory support with oxygen and BIPAP, if needed.

In conclusion, we found that the avoidance of muscle relaxants and use of remifentanil and a low-dose hypnotic agent can provide a stable intraoperative course, rapid emergence, and early extubation in patients with JMG undergoing transsternal thymectomy. Adequate postoperative analgesia can be achieved with the use of epidural analgesia, without detrimental effect on postoperative recovery.
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